13 terminated. 13 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 13 | Terminated 13 |
Follow Hyperlipidemias: new trials by email Literature Review of Hyperlipidemias trials Research Report on Hyperlipidemias
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| The CHORAL Flow Study Evolocumab, Placebo - Coronary Artery Disease, Atherosclerosis | Phase 4 | Terminated | Imperial College London | 12 | 2019-09-11 | 2024-08-06 |
| Impact of LDL-cholesterol Lowering on Platelet Activation Evolocumab - Familial Hypercholesterolemia | Phase 4 | Terminated | Columbia University | 4 | 2018-11-16 | 2021-04-01 |
| Investigating the Effects of Lipid-therapy Intensification With Alirocumab on Endothelial Function, Carotid Arteries, Lipoprotein Particle Subfractions, Inflammation and Post-prandial Lipemia Magnet Resonance Tomography, Carotid Arteries Sonography, Flow-mediated Dilation, Fat-tolerance Test, Laboratory Testing - Atherosclerosis, Hypercholesterolemia | Phase 4 | Terminated | Medical University of Graz | 24 | 2018-06-20 | 2020-04-24 |
| Anti-inflammatory Effects of Simvastatin Simvastatin 40mg, Ezetimibe 10mg - Inflammation, Atherosclerosis | Phase 4 | Terminated | paresh Dandona | 10 | 2017-05-01 | 2024-11-08 |
| Study Evaluating Novel Biomarkers of AKI (Acute Kidney Injury) in Post-operative Patients Nephro Check Test, serum creatinine measurement - Acute Kidney Injury, Arterial Hypertension | Phase 4 | Terminated | Universitair Ziekenhuis Brussel | 100 | 2015-04-01 | 2018-10-15 |
| Effect of Niacin/Laropiprant on Postprandial Lipoprotein Metabolism in Patients With Dyslipoproteinemia Niacin/ Laropiprant - Hyperlipoproteinemia, Metabolic Syndrome | Phase 4 | Terminated | Ludwig-Maximilians - University of Munich | 12 | 2011-06-01 | 2014-04-10 |
| Evaluating the Efficacy and Safety of Dehypotin® in the Patients With Type 2 Diabetes Mellitus or Cardiovascular Disease Placebo, Dehypotin - Type 2 Diabetes Mellitus, Cardiovascular Disease | Phase 4 | Terminated | Nang Kuang Pharmaceutical Co., Ltd. | 60 | 2010-05-01 | 2011-06-09 |
| The Effect of Atorvastatin on Endothelial Cell Dysfunction in Chronic Kidney Disease Atorvastatin - Chronic Kidney Disease, High Cholesterol | Phase 4 | Terminated | Duke University | 1 | 2008-02-01 | 2014-07-03 |
| Study of Asian Patients With Hypercholesterolaemia in the UK - Rosuvastatin 5mg Versus Atorvastatin 10mg Dietary advice, rosuvastatin, atorvastatin - Hypercholesterolaemia | Phase 4 | Terminated | AstraZeneca | 55 | 2006-12-01 | 2010-12-16 |
| Randomized Trial Comparing N of 1 Trials to Standard Practice to Improve Adherence to Statins in Patients With Diabetes N of 1 Trials - Diabetes, Cardiovascular Disease | Phase 4 | Terminated | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | 6 | 2006-09-01 | 2008-01-08 |
| Switching to Rosuvastatin Versus Adding Ezetimibe to Atorvastatin Versus Doubling the Dose of Atorvastatin in Patients With Hypercholesterolemia and Risk Factors (P03708) Rosuvastatin, Ezetimibe + Atorvastatin, Double Atorvastatin - Hypercholesterolemia, Atherosclerosis | Phase 4 | Terminated | Organon and Co | 87 | 2004-09-01 | 2024-08-15 |
| Ezetimibe Plus Simvastatin Versus Simvastatin in Patients With Hypercholesterolemia and Coronary Risk Factors (P03405) Ezetimibe, Placebo - Hypercholesterolemia, Atherosclerosis | Phase 4 | Terminated | Organon and Co | 82 | 2004-01-01 | 2022-02-17 |
| Atorvastatin and LDL Profile in Non-Insulin Dependent Diabetes Mellitus Atorvastatin, Placebo - Hyperlipidemia, Diabetes Mellitus, Type 2 | Phase 4 | Terminated | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | 41 | 2003-03-01 | 2021-02-18 |
Hypercholesterolemia (9) · Atherosclerosis (5) · Cardiovascular Diseases (3) · Coronary Artery Disease (2) · Diabetes Mellitus (2) · Diabetes Mellitus, Type 2 (2) · Acute Kidney Injury (1) · Hyperlipoproteinemia Type II (1) · Hyperlipoproteinemias (1) · Hypertension (1) · Inflammation (1) · Metabolic Syndrome (1) · Obesity (1) · Renal Insufficiency, Chronic (1)
Dyslipidemias (13) · Lipid Metabolism Disorders (13) · Metabolic Diseases (13) · Nutritional and Metabolic Diseases (13) · Vascular Diseases (7) · Cardiovascular Diseases (6) · Arterial Occlusive Diseases (5) · Arteriosclerosis (5) · Glucose Metabolism Disorders (5) · Endocrine System Diseases (4) · Pathological Conditions, Signs and Symptoms (3) · Coronary Disease (2) · Diabetes Mellitus (2) · Female Urogenital Diseases (2)
Atorvastatin (4) · Ezetimibe (3) · Rosuvastatin Calcium (2) · evolocumab (2) · MK-0524 (1) · Niacin (1) · Nutrition Assessment (1) · Simvastatin (1) · Single-Case Studies as Topic (1)
Organon and Co (2) · AstraZeneca (1) · Columbia University (1) · Duke University (1) · Imperial College London (1) · London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's (1) · Ludwig-Maximilians - University of Munich (1) · Medical University of Graz (1) · Nang Kuang Pharmaceutical Co., Ltd. (1) · Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (1) · Universitair Ziekenhuis Brussel (1) · paresh Dandona (1)
Germany (2) · United Kingdom (2) · United States (2) · Austria (1) · Belgium (1) · Canada (1) · Taiwan (1)
Charlotte G McDonald, MD (1) · Henry Ginsberg, MD (1) · Henry Seligman, MBBS (1) · Jan Poelaert, Prof.Dr. (1) · Klaus Parhofer, MD, Prof. (1) · Lien Torisaen, MD (1) · Lynda Szczech, MD (1) · Nan Wang, PhD (1) · Paresh Dandona, MD, PhD (1) · Rhiannon Rowsell, MD (1) · Ricardo Petraco, PhD (1) · Shahid Ali, MD (1) · Yang Wei Shiung (1)
2018 (1)